What Sintetica does

Sintetica SA is a Swiss specialty pharmaceutical company founded in 1921 and headquartered in Mendrisio, Switzerland, focused on the development, manufacturing, and commercialization of sterile injectable solutions. Its portfolio spans anaesthesia, pain management, neuromodulation, and intensive care, with a flagship Premix® platform that delivers premixed, ready-to-use, preservative-free formulations designed to eliminate bedside drug manipulation. The company operates two FDA-approved manufacturing sites in Switzerland — Mendrisio (ampoules) and Couvet (vials and infusion bags) — with combined annual capacity of approximately 90 million ampoules, 8 million vials, and 5 million infusion bags, and markets 250+ products across more than 50 countries.

Sintetica's business model is a hybrid of direct sales and licensed distribution. In Switzerland, Germany, and Austria, specialized national sales teams sell directly to hospitals and clinicians; outside these markets, the company relies on licensing and distribution partnerships with top-tier international players. Revenue (2024 disclosure) is geographically diversified at 32% Switzerland, 25% Germany & Austria, 25% United States, and 18% Rest of World, and split 41% B2B and 59% B2C across therapeutic areas led by Emergency & Intensive Care (45%), Anaesthesia (24%), Analgesics (22%), and Neuromodulation (9%). Notable branded assets include Ampres® (the first chloroprocaine approved for spinal anaesthesia in Europe), Takipril® (hyperbaric prilocaine), and IHEEZO™ (an ophthalmic gel licensed to Harrow in the U.S. and Canada, protected by Orange Book-listed patents until 2038).

The company has been majority-owned by French private equity firm Ardian since May 2019, with a confirmed 60 million CHF four-year investment plan supporting globalization. Sintetica has 16 granted patents, an Innovation Cluster combining pharmaceutical, medical, and industrial development, and a 2024 management refresh including a new Executive Chairman/CEO (Dr. Hubert Puech d'Alissac), CFO (Dr. Luca Scavo), and independent director (Brendan O'Grady, formerly of Teva and Glenmark) — moves consistent with a commercial scaling and U.S. market entry strategy that began with the 2023 FDA approval of the Couvet site.

Name

Sintetica

Legal name

SINTETICA SA

Website

https://sintetica.com

Company type

Private

Founded year

1921

Operating status

Operating

Short description

Sintetica is a Swiss specialty pharmaceutical company that develops and manufactures sterile injectable drugs in anaesthesia, pain management, neuromodulation, and intensive care, selling through direct hospital sales in DACH and licensed distributors across 50+ countries.

Ownership category

akta.pro rank

Product category

Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Sterile Injectable Generics (HLAIABAC), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Sterile injectable drugs
• Pharmaceutical manufacturing
• Anaesthesia medications
• Pain management drugs
• Intensive care pharmaceuticals

Headquarters

HQ city

Mendrisio

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Direct Pharmaceutical Sales: Sintetica directly sells and markets its pharmaceutical products (anaesthesia, pain management, neuromodulation, intensive care) in Switzerland, Germany, and Austria through specialized national sales teams. Products include over 250 formulations sold in 50+ countries.
2. Licensing and Distribution Partnerships: Sintetica licenses its products to commercial partners worldwide. The company runs sales subsidiaries in selected European markets and partners with leading distributors around the world for markets outside its direct presence.
3. International Business Development: The company offers a dynamic portfolio of selected branded and generic products developed to address niche and unmet clinical needs, built through strong and long-lasting alliances with international partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Sintetica researches, develops, manufactures, and markets sterile injectable pharmaceutical products in ampoules, vials, and IV bags for anaesthesia, pain management, neuromodulation, and intensive care. The portfolio includes over 250 marketed formulations across proprietary brands (Premix®, Ampres®, Takipril®, IHEEZO™) and generic injectable drugs, produced at two FDA-approved Swiss manufacturing sites and distributed directly in Switzerland, Germany, and Austria and through licensing partners in 50+ countries.

Product overview

Sintetica is a Swiss pharmaceutical company that develops and manufactures a comprehensive portfolio of injectable medications for anesthesia, pain management, neuromodulation, and intensive care. The company operates two FDA-approved production sites in Switzerland (Mendrisio and Couvet) and produces liquid sterile injectable solutions in ampoules, vials, and IV bags. Their core products include 14 main injectable medications (Baclofen, Bupivacaine, Chloroprocaine, Droperidol, Ephedrine, Glycopyrrolate/Neostigmine, Heparin, Hydromorphone, Ketamine, Midazolam, Noradrenaline, Paracetamol, Phenylephrine, and Ropivacaine). Key branded offerings include IHEEZO™ ophthalmic gel and the Premix® platform for ready-to-use formulations. The company also focuses on therapeutic approaches like One Day Surgery and Enhance Intrathecal Therapy, targeting day surgery, perioperative care, and neuromodulation applications.

Differentiator

Problem solved

Functional benefit

Brands

• Premix: Premixed medicines that increase safety of therapy by direct administration without previous dilution, reducing time and complexity of drug preparation.
• Takipril
• Ampres

Products and services

• Baclofen Inj Injectable muscle relaxant medication used in pain management and neuromodulation therapies, supplied to hospitals for intrathecal and pain care applications.
• Bupivacaine Inj Long-acting local anaesthetic injection used for regional anaesthesia in surgical procedures.
• Chloroprocaine Inj / Gel (Ampres®) Short-acting local anaesthetic in injectable and gel formulations, including the Ampres® spinal formulation and chloroprocaine-based ophthalmic gels supplied to hospitals and surgical centers.
• Droperidol Inj Antipsychotic and antiemetic injectable medication used in anaesthesia and perioperative care.
• Ephedrine HCl Inj Vasopressor injection used for treatment of hypotension during anaesthesia.
• Glycopyrrolate & Neostigmine Inj Combination injection used to reverse neuromuscular blockade after surgery.
• Heparine Inj Anticoagulant injection used in intensive care and surgical settings.
• Hydromorphone Inj Potent opioid analgesic injection for severe pain management in perioperative and critical-care settings.
• Ketamine HCl Inj Dissociative anaesthetic injection used for induction and maintenance of anaesthesia and in pain management.
• Midazolam Inj Benzodiazepine injection used for sedation, anaesthesia induction, and anxiety management in critical care.
• Noradrenaline Inj Vasoconstrictor emergency life-saving drug used for treatment of hypotonia and shock states.
• Paracetamol Inj Intravenous analgesic injection for pain and fever management in hospital settings.
• Phenylephrine HCl Inj Alpha-adrenergic agonist injection used for treatment of hypotension during anaesthesia.
• Ropivacaine HCl Inj Long-acting local anaesthetic injection suitable for regional anaesthesia and pain management, including day-surgery applications.
• IHEEZO™ Chloroprocaine hydrochloride ophthalmic gel 3% for ocular surface anaesthesia. Sterile, single-patient-use, physician-administered preparation containing no preservatives, sold to ophthalmology clinics and hospitals.
• Premix® Platform Proprietary platform of premixed, ready-to-use injectable medicines that increase therapy safety by enabling direct administration without prior dilution, reducing time and complexity of drug preparation in hospital settings.
• Takipril® Patented hyperbaric Prilocaine formulation for spinal administration in short-duration surgeries, sold to hospitals for day surgery and spinal anaesthesia use.

Quantifiable outcome

• FDA approval for Couvet production site in 2023 with no deviations found
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Meduna GmbHcoreStrategic or Co-development Partner · 8 May 2013Sintetica acquired Meduna GmbH in 2013 and established Sintetica GmbH as its first foreign subsidiary in Germany, enabling direct service of the German and Austrian markets. In 2016, Sintetica GmbH moved to a new larger location in Münster, Westphalia.
• Bioren SA (Couvet)coreStrategic or Co-development Partner · 1 January 2005Sintetica acquired Bioren SA in 2005, one of its suppliers of vials and infusion bags, forming Sintetica-Bioren SA as the second manufacturing plant in Switzerland. Augusto Mitidieri was appointed CEO and Luca Bolzani was President of the Board following the acquisition.

Scale indicators10 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Fresenius Kabi: German-headquartered specialist in sterile injectable pharmaceuticals, anaesthesia, pain management, and clinical nutrition. Directly comparable to Sintetica in therapeutic focus (anaesthesia/pain injectables), sterile injectable manufacturing, and B2B hospital-channel commercialization across multiple geographies.
• B. Braun: Family-owned German medical device and pharmaceutical company with a sizable sterile injectable and anaesthesia portfolio, serving hospitals globally. Overlaps directly with Sintetica on local anaesthetics, peri-operative injectables, and DACH-centered hospital commercialization.
• ICU Medical: US-based pure-play sterile injectable and IV therapy company serving hospitals and alternate-care sites. Comparable to Sintetica as a focused sterile injectable manufacturer with US regulatory depth (FDA-inspected facilities) and a similar product-form mix (bags, vials, syringes).
• Hikma Pharmaceuticals: UK-listed specialty and injectable pharmaceutical company with a large sterile injectable generics portfolio sold to hospitals worldwide. Highly comparable to Sintetica in product form (sterile injectables), hospital channel, and international licensing/distributor model outside direct markets.
• Dr. Reddy's Laboratories: Indian-headquartered global pharmaceutical company with a growing sterile injectable portfolio (incl. anaesthesia/analgesics) and a multi-continent commercial footprint. Comparable to Sintetica as a focused injectable pharmaceutical manufacturer scaling internationally through partnerships and direct sales.

Broad incumbents

• Baxter International: Global hospital-products leader with a major sterile injectable, IV solutions, and anaesthesia franchise. Overlaps with Sintetica on ampoules, vials and IV bags in the same hospital call points, though Baxter operates a much broader medical products portfolio beyond injectables.
• Pfizer (Injectables): World's largest pharmaceutical company, holding the legacy Hospira sterile injectable generics portfolio that competes head-to-head in anaesthetics, analgesics, and peri-operative injectables. Significantly larger than Sintetica but a direct competitor in the US hospital injectable channel that Sintetica is now entering.
• Teva Pharmaceutical Industries: Global leader in generic injectable pharmaceuticals, particularly anaesthesia and pain management injectables, and a direct US-market competitor through its hospital business. Brendon O'Grady, Sintetica's new independent director, previously led Teva North America; relevant executive overlap as well as product overlap.
• Sandoz (Novartis): Spin-off of Novartis and one of the world's largest generic injectable pharmaceutical companies, with a broad peri-operative and hospital injectable portfolio. Comparable to Sintetica as a global sterile injectable competitor; considerably larger scale than Sintetica but a direct set of head-to-head hospital injectable products.

Emerging players

• Aspen Pharmacare: South African pharmaceutical group with a global sterile injectable and anaesthesia presence, particularly strong in emerging markets. Comparable to Sintetica in therapeutic focus (anaesthesia/pain) and product form (sterile injectables), though a different geographic anchor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sintetica-sa

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sintetica